HOME >> BIOLOGY >> NEWS
New advances in thrombosis help further understanding of disease prevention

eemed to experience a higher incidence of major bleeding over that of standard therapy (0.7 percent - 25 mg bid; 4.1 percent - 50 mg bid; 3.5 percent - 75 mg bid; and 5.8 percent - 100 mg bid versus 0.0 percent - enoxaparin 30 mg bid). The three highest doses of razaxaban were stopped before the intended sample size of 150 patients was reached, due to increased reports of bleeding. In this study, the lowest dose of razaxaban, 25 mg bid, demonstrated potential for increased efficacy and similar safety compared to current standard treatment.

Randomized, Double-Blind Comparison of Ximelagatran, an Oral Direct Thrombin Inhibitor, and Warfarin to Prevent Venous Thromboembolism (VTE) after Total Knee Replacement (TKR): EXULT B (Abstract 39)

Total knee replacement surgery, like many other major orthopedic surgeries, continues to be hampered by venous thromboembolism events, such as deep vein thrombosis and pulmonary embolism. Without any preventive medication, harmful blood clots occur in two thirds of all total knee replacement surgery patients. Anticoagulants that are currently approved in the U.S. for prevention of venous thromboembolism are still associated with unacceptably high rates of deep vein thrombosis and require regular dosage monitoring to prevent major bleeding events.

"Oral anticoagulants that are currently available have many limitations. There is a great need for new therapies with increased safety and efficacy," said Charles Francis, M.D., of the University of Rochester, Rochester, N.Y., lead investigator of the study. "The results from this study encourage us to continue looking at ximelagatran as a preventive treatment for this serious complication in total knee replacement surgery."

The trial, led by Dr. Francis, compares the safety and efficacy of ximelagatran, a novel oral direct thrombin inhibitor, to warfarin for prevention of venous thromboembolism in total knee replacement patients.
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Society of Hematology
6-Dec-2003


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Grant advances biochemical engineering laboratory
2. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
3. Undergraduate research experience advances education
4. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
5. UCSF finding advances insight into adult stem cells in human brain
6. Federal grant supports advances in infant heart disease at Childrens Hospital of Philadelphia
7. Human embryonic stem cells may promise medical advances
8. Scientists making advances in cancer prevention, detection and treatment to receive awards
9. Conference to highlight medical advances resulting from 50 years of DNA knowledge
10. Annual bibliography of significant advances in dietary supplement research 2002
11. Dartmouth study advances prion disease research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new ... rates in frozen and fresh in vitro fertilization (IVF) transfer cycles. ... to IVF success. , After comparing the results from the fresh and frozen ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology:
Cached News: